These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 38454445)

  • 1. S100A9
    Tu X; Chen L; Zheng Y; Mu C; Zhang Z; Wang F; Ren Y; Duan Y; Zhang H; Tong Z; Liu L; Sun X; Zhao P; Wang L; Feng X; Fang W; Liu X
    J Exp Clin Cancer Res; 2024 Mar; 43(1):72. PubMed ID: 38454445
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Glycolytic activation of peritumoral monocytes fosters immune privilege via the PFKFB3-PD-L1 axis in human hepatocellular carcinoma.
    Chen DP; Ning WR; Jiang ZZ; Peng ZP; Zhu LY; Zhuang SM; Kuang DM; Zheng L; Wu Y
    J Hepatol; 2019 Aug; 71(2):333-343. PubMed ID: 31071366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sensitizing tumors to anti-PD-1 therapy by promoting NK and CD8+ T cells via pharmacological activation of FOXO3.
    Chung YM; Khan PP; Wang H; Tsai WB; Qiao Y; Yu B; Larrick JW; Hu MC
    J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34887262
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anlotinib potentiates anti-PD1 immunotherapy via transferrin receptor-dependent CD8
    Song F; Hu B; Liang XL; Cheng JW; Wang CG; Wang PX; Wang TL; Tang PJ; Sun HX; Guo W; Zhou J; Fan J; Chen Z; Yang XR
    Clin Transl Med; 2024 Aug; 14(8):e1738. PubMed ID: 39095323
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ultra-thin layered double hydroxide-mediated photothermal therapy combine with asynchronous blockade of PD-L1 and NR2F6 inhibit hepatocellular carcinoma.
    Lu YF; Zhou JP; Zhou QM; Yang XY; Wang XJ; Yu JN; Zhang JG; Du YZ; Yu RS
    J Nanobiotechnology; 2022 Jul; 20(1):351. PubMed ID: 35907841
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting immunosuppressive Ly6C+ classical monocytes reverses anti-PD-1/CTLA-4 immunotherapy resistance.
    Rodriguez BL; Chen L; Li Y; Miao S; Peng DH; Fradette JJ; Diao L; Konen JM; Alvarez FRR; Solis LM; Yi X; Padhye A; Gibson LA; Ochieng JK; Zhou X; Wang J; Gibbons DL
    Front Immunol; 2023; 14():1161869. PubMed ID: 37449205
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intrahepatic inflammatory IgA
    Sung PS; Park DJ; Roh PR; Mun KD; Cho SW; Lee GW; Jung ES; Lee SH; Jang JW; Bae SH; Choi JY; Choi J; Ahn J; Yoon SK
    J Immunother Cancer; 2022 May; 10(5):. PubMed ID: 35577505
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeting monocyte-intrinsic enhancer reprogramming improves immunotherapy efficacy in hepatocellular carcinoma.
    Liu M; Zhou J; Liu X; Feng Y; Yang W; Wu F; Cheung OK; Sun H; Zeng X; Tang W; Mok MTS; Wong J; Yeung PC; Lai PBS; Chen Z; Jin H; Chen J; Chan SL; Chan AWH; To KF; Sung JJY; Chen M; Cheng AS
    Gut; 2020 Feb; 69(2):365-379. PubMed ID: 31076403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MTDH antisense oligonucleotides reshape the immunosuppressive tumor microenvironment to sensitize Hepatocellular Carcinoma to immune checkpoint blockade therapy.
    Wan JL; Wang B; Wu ML; Li J; Gong RM; Song LN; Zhang HS; Zhu GQ; Chen SP; Cai JL; Xing XX; Wang YD; Yang Y; Cai CZ; Huang R; Liu H; Dai Z
    Cancer Lett; 2022 Aug; 541():215750. PubMed ID: 35609735
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Protein O-fucosyltransferase 1 promotes PD-L1 stability to drive immune evasion and directs liver cancer to immunotherapy.
    Li Q; Guo W; Qian Y; Li S; Li L; Zhu Z; Wang F; Tong Y; Xia Q; Liu Y
    J Immunother Cancer; 2024 Jun; 12(6):. PubMed ID: 38908854
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Uncoupling immune trajectories of response and adverse events from anti-PD-1 immunotherapy in hepatocellular carcinoma.
    Chuah S; Lee J; Song Y; Kim HD; Wasser M; Kaya NA; Bang K; Lee YJ; Jeon SH; Suthen S; A'Azman S; Gien G; Lim CJ; Chua C; Hazirah SN; Lee HK; Lim JQ; Lim TKH; Yeong J; Chen J; Shin EC; Albani S; Zhai W; Yoo C; Liu H; Choo SP; Tai D; Chew V
    J Hepatol; 2022 Sep; 77(3):683-694. PubMed ID: 35430299
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FXa-mediated PAR-2 promotes the efficacy of immunotherapy for hepatocellular carcinoma through immune escape and anoikis resistance by inducing PD-L1 transcription.
    Li X; Gao L; Wang B; Hu J; Yu Y; Gu B; Xiang L; Li X; Li H; Zhang T; Wang Y; Ma C; Dong J; Lu J; Lucas A; Chen H
    J Immunother Cancer; 2024 Jul; 12(7):. PubMed ID: 39060025
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy.
    Li Q; Han J; Yang Y; Chen Y
    Front Immunol; 2022; 13():1070961. PubMed ID: 36601120
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TNF-α-Secreting Lung Tumor-Infiltrated Monocytes Play a Pivotal Role During Anti-PD-L1 Immunotherapy.
    De Ridder K; Locy H; Piccioni E; Zuazo MI; Awad RM; Verhulst S; Van Bulck M; De Vlaeminck Y; Lecocq Q; Reijmen E; De Mey W; De Beck L; Ertveldt T; Pintelon I; Timmermans JP; Escors D; Keyaerts M; Breckpot K; Goyvaerts C
    Front Immunol; 2022; 13():811867. PubMed ID: 35493461
    [TBL] [Abstract][Full Text] [Related]  

  • 15. IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma.
    Zhang W; Liu Y; Yan Z; Yang H; Sun W; Yao Y; Chen Y; Jiang R
    J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581055
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas.
    Zhou G; Sprengers D; Boor PPC; Doukas M; Schutz H; Mancham S; Pedroza-Gonzalez A; Polak WG; de Jonge J; Gaspersz M; Dong H; Thielemans K; Pan Q; IJzermans JNM; Bruno MJ; Kwekkeboom J
    Gastroenterology; 2017 Oct; 153(4):1107-1119.e10. PubMed ID: 28648905
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Increased both PD-L1 and PD-L2 expressions on monocytes of patients with hepatocellular carcinoma was associated with a poor prognosis.
    Yasuoka H; Asai A; Ohama H; Tsuchimoto Y; Fukunishi S; Higuchi K
    Sci Rep; 2020 Jun; 10(1):10377. PubMed ID: 32587357
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined Effects of Anti-PD-L1 and Nanosonodynamic Therapy on HCC Immune Activation in Mice: An Investigation.
    Wei M; Wang X; Mo Y; Kong C; Zhang M; Qiu G; Tang Z; Chen J; Wu F
    Int J Nanomedicine; 2024; 19():7215-7236. PubMed ID: 39050875
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Radiation improves antitumor effect of immune checkpoint inhibitor in murine hepatocellular carcinoma model.
    Kim KJ; Kim JH; Lee SJ; Lee EJ; Shin EC; Seong J
    Oncotarget; 2017 Jun; 8(25):41242-41255. PubMed ID: 28465485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade.
    Zhu Y; Yang J; Xu D; Gao XM; Zhang Z; Hsu JL; Li CW; Lim SO; Sheng YY; Zhang Y; Li JH; Luo Q; Zheng Y; Zhao Y; Lu L; Jia HL; Hung MC; Dong QZ; Qin LX
    Gut; 2019 Sep; 68(9):1653-1666. PubMed ID: 30902885
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.